{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:20:08Z","timestamp":1790011208653,"version":"4.0.1"},"reference-count":16,"publisher":"BMJ","issue":"6","funder":[{"name":"Pfizer Products India Private Limited","award":["63631449"],"award-info":[{"award-number":["63631449"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2021,2,22]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      Anaplastic lymphoma kinase (\n                      <jats:italic>ALK<\/jats:italic>\n                      ) rearranged non-small cell lung carcinoma (NSCLC) is a distinct molecular subtype and rapid approval of\n                      <jats:italic>ALK<\/jats:italic>\n                      tyrosine kinase inhibitors (TKIs) has necessitated rapid and sensitive diagnostic modalities for the detection of this alteration. Gene rearrangements can be identified using many techniques including fluorescence in situ hybridisation (FISH), reverse transcriptase-PCR, next-generation sequencing (NGS) and immunohistochemistry (IHC) for fusion oncoprotein expression. We aimed to determine the concordance between IHC, FISH and NGS for\n                      <jats:italic>ALK<\/jats:italic>\n                      biomarker detection, and determine differences in sensitivity, and survival outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analysed the concordance between IHC using D5F3 monoclonal antibody, FISH (break-apart) and NGS using a custom panel containing 71 different\n                      <jats:italic>ALK<\/jats:italic>\n                      variants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 71 cases included in this study, FISH was evaluable in 58 cases. The concordance of ALK IHC with FISH was 75.9% and that with NGS was 84.5%. The sensitivities of FISH and NGS were 75.6% and 87.5%, respectively. The median progression-free survival of ALK IHC-positive and FISH-negative group was 5.5 months and that of both positive was 9.97 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although NGS offers a better throughput and visualisation, IHC still remains the quintessential screening tool in upfront diagnosis of ALK rearranged NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jclinpath-2021-207408","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T13:20:56Z","timestamp":1616419256000},"page":"405-409","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["IHC versus FISH versus NGS to detect ALK gene rearrangement in NSCLC: all questions answered?"],"prefix":"10.1136","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3306-9824","authenticated-orcid":false,"given":"Ullas","family":"Batra","sequence":"first","affiliation":[{"name":"Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrinidhi","family":"Nathany","sequence":"additional","affiliation":[{"name":"Molecular Diagnostics, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Sharma","sequence":"additional","affiliation":[{"name":"Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Pasricha","sequence":"additional","affiliation":[{"name":"Pathology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Bansal","sequence":"additional","affiliation":[{"name":"Radiology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parveen","family":"Jain","sequence":"additional","affiliation":[{"name":"Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6517-3664","authenticated-orcid":false,"given":"Anurag","family":"Mehta","sequence":"additional","affiliation":[{"name":"Laboratory Services, Transfusion Medicine and Research, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"2025112108100761000_75.6.405.1","unstructured":"Network NCCN . Non-Small cell lung cancer (version 3) 2020."},{"key":"2025112108100761000_75.6.405.2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jtho.2017.01.020","article-title":"A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib","volume":"12","author":"Thorne-Nuzzo","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2025112108100761000_75.6.405.3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2019.08.416","article-title":"Phase 3 ALUR Study of Alectinib in Pretreated ALK SCLC\u202f: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses A Non-Randomized, Open-Label, Prospective, Multicenter Study of Apatinib as Second-Line and Later-Line Therapy in Patients with","volume":"14","author":"Wolf","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2025112108100761000_75.6.405.4","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000419"},{"key":"2025112108100761000_75.6.405.5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1631"},{"key":"2025112108100761000_75.6.405.6","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.21037\/jtd.2019.12.25","article-title":"Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients","volume":"11","author":"Nong","year":"2019","journal-title":"J Thorac Dis"},{"key":"2025112108100761000_75.6.405.7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jtho.2017.11.117","article-title":"Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results from the European thoracic oncology platform Lungscape project","volume":"13","author":"Letovanec","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025112108100761000_75.6.405.8","doi-asserted-by":"crossref","first-page":"82943","DOI":"10.18632\/oncotarget.12705","article-title":"ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma","volume":"7","author":"Dacic","year":"2016","journal-title":"Oncotarget"},{"key":"2025112108100761000_75.6.405.9","first-page":"30815","article-title":"Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study","volume":"S1556-0864","author":"Mok","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2025112108100761000_75.6.405.10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5301\/jbm.5000218","article-title":"ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis","volume":"31","author":"Pyo","year":"2016","journal-title":"Int J Biol Markers"},{"key":"2025112108100761000_75.6.405.11","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0389"},{"key":"2025112108100761000_75.6.405.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1468-9","article-title":"Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib","volume":"16","author":"Xu","year":"2018","journal-title":"J Transl Med"},{"key":"2025112108100761000_75.6.405.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.03.018"},{"key":"2025112108100761000_75.6.405.14","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.2147\/OTT.S265974","article-title":"Comparison of next-generation sequencing and Ventana immunohistochemistry in detecting ALK rearrangements and predicting the efficacy of first-line crizotinib in patients with advanced non-small cell lung cancer","volume":"13","author":"Zeng","year":"2020","journal-title":"Onco Targets Ther"},{"key":"2025112108100761000_75.6.405.15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.tranon.2018.11.006","article-title":"Discordance between FISH, IHC, and NGS analysis of ALK status in advanced non-small cell lung cancer (NSCLC): a brief report of 7 cases","volume":"12","author":"Scattone","year":"2019","journal-title":"Transl Oncol"},{"key":"2025112108100761000_75.6.405.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.12.004"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2021-207408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T16:10:18Z","timestamp":1763741418000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2021-207408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,5,19]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/jclinpath-2021-207408"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2021-207408","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]}}}